Nanobiotix S.A Change in Accounts Receivable 2020-2024 | NBTX

Nanobiotix S.A change in accounts receivable from 2020 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Nanobiotix S.A Change in Accounts Receivable 2020-2024 | NBTX

Nanobiotix S.A change in accounts receivable from 2020 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$71.1B
Zoetis (ZTS)$68.9B
Takeda Pharmaceutical (TAK)$47.3B
Daiichi Sankyo, - (DSNKY)$46B
BeOne Medicines - (ONC)$32.9B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$18.4B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.7B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.7B
Orion OYJ (ORINY)$11.2B
IPSEN (IPSEY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.4B
Eisai (ESAIY)$9.1B
Corcept Therapeutics (CORT)$7.3B
Ionis Pharmaceuticals (IONS)$6.8B
Stevanato Group S.p.A (STVN)$6.8B
Grifols, S.A (GRFS)$6.7B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
Hypermarcas (HYPMY)$2.8B
Procaps Group, S.A (PROCF)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B